A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
Authors:
- Alain NguyenANAlain Nguyen
- Alexandra CalmyACAlexandra Calmy
- Cecile DelhumeauCDCecile Delhumeau
- Isabelle MercierIMIsabelle Mercier
- Matthias CavassiniMCMatthias Cavassini
- Aurelie F. MelloAMAurelie F. Mello
- Luigia ElziLELuigia Elzi
- Andri RauchARAndri Rauch
- Enos BernasconiEBEnos Bernasconi
- Patrick SchmidPSPatrick Schmid
- Bernard HirschelBHBernard Hirschel
- 31 July 2011
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 25 (12) , 1481-1487
Abstract
Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavorable blood lipid profile. We investigated the effect of replacing EFV with raltegravir (RAL) on patient preference, daytime sleepiness, sleep quality, anxiety, and lipid levels. Switch-ER was a randomized, double-blind, cross-over study. Patients who tolerated EFV, with less than 50 copies/ml HIV-RNA, were randomized into two groups: the RAL-first group started with RAL (400 mg twice daily) and EFV placebo, and the EFV-first group with EFV (600 mg once daily) and RAL placebo. After 2 weeks, both groups switched to the alternate regimen. The primary endpoint was patient preference for the first or the second regimen, assessed after 4 weeks. Fifty seven participants were enrolled with a median CD4 cell count 600/μl, and duration of previous EFV therapy 3.4 years. Fifty three participants completed the study. When asked about treatment preference after 4 weeks, 22 preferred RAL and 12 preferred EFV, whereas 19 did not express a preference. A significant difference in anxiety and stress scores favoring RAL (P = 0.04 and 0.03, respectively) was observed. Median plasma cholesterol levels decreased by 0.4 mmol/l (16 mg/dl, P < 0.001), triglycerides by 0.2 mmol/l (18 mg/dl, P = 0.036), and low-density lipoprotein by 0.2 mmol/l (8 mg/dl, P = 0.004) after replacing EFV with RAL. After study completion, 51% of patients switched to RAL. Half of patients previously on a stable EFV preferred to switch to RAL, after double-blind exposure to RAL for 2 weeks. Substitution of EFV by RAL significantly impacted on lipid levels, stress, and anxiety scores.Keywords
This publication has 21 references indexed in Scilit:
- A randomized crossover study to compare efavirenz and etravirine treatmentAIDS, 2011
- A LC–tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirineJournal of Chromatography B, 2009
- Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free FractionTherapeutic Drug Monitoring, 2008
- No patient left behind—better treatments for resistant HIV infectionThe Lancet, 2007
- Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometryJournal of Chromatography B, 2005
- Long-Term Neuropsychiatric Disorders on Efavirenz-Based ApproachesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz Versus Protease Inhibitor–Containing RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- EfavirenzDrugs, 1998
- Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samplesBehaviour Research and Therapy, 1997